



## The effect of combined remifentanil and low dose ketamine infusion in patients undergoing laparoscopic gastric bypass

Riham Hasanein, Wael El-Sayed, Nashwa Nabil & Ghada Elsayed

To cite this article: Riham Hasanein, Wael El-Sayed, Nashwa Nabil & Ghada Elsayed (2011) The effect of combined remifentanil and low dose ketamine infusion in patients undergoing laparoscopic gastric bypass, Egyptian Journal of Anaesthesia, 27:4, 255-260, DOI: [10.1016/j.egja.2011.07.009](https://doi.org/10.1016/j.egja.2011.07.009)

To link to this article: <https://doi.org/10.1016/j.egja.2011.07.009>



© 2011 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.



Published online: 17 May 2019.



Submit your article to this journal [↗](#)



Article views: 112



View related articles [↗](#)



Citing articles: 8 View citing articles [↗](#)



Egyptian Society of Anesthesiologists  
**Egyptian Journal of Anaesthesia**

www.elsevier.com/locate/egja  
www.sciencedirect.com



Research Article

# The effect of combined remifentanil and low dose ketamine infusion in patients undergoing laparoscopic gastric bypass

Riham Hasanein <sup>a,\*</sup>, Wael El-Sayed <sup>a</sup>, Nashwa Nabil <sup>a</sup>, Ghada Elsayed <sup>b</sup>

<sup>a</sup> Department of Anesthesia, Cairo University, Cairo, Egypt

<sup>b</sup> Department of Anesthesia, National Cancer Institute, Cairo, Egypt

Received 13 May 2011; revised 22 July 2011; accepted 26 July 2011  
Available online 9 September 2011

## KEYWORDS

Ketamine infusion;  
Remifentanil;  
Gastric bypass

**Abstract** *Background:* The choice of anesthesia in morbidly obese patients remains controversial. We evaluated the effect of continuous low dose ketamine infusion combined with remifentanil and propofol in patients undergoing laparoscopic gastric bypass, on hemodynamic stability, postoperative analgesic requirement and recovery profile.

*Methods:* 60 patients aged 25–50 years, allocated into 2 groups. Group I: received continuous infusion of (propofol 6–10 mg/kg/h + remifentanil 0.2 µg/kg/min + saline). Group II: received continuous infusion of (propofol 6–10 mg/kg/h + remifentanil 0.2 µg/kg/min + ketamine 1µg/kg/min). All patients received intravenous morphine by patient controlled analgesia (PCA) postoperatively. Mean blood pressure and HR, duration of anesthesia and surgery recorded. Bispectral index, total amount of propofol and remifentanil used intraoperative were measured. In the recovery room, time to response to verbal commands was recorded, subjective pain scores were obtained with a scale from 0–10. Postoperative nausea and vomiting, hallucinations were recorded. Early pain perception and total consumption of morphine in 24 h recorded.

*Results:* During anesthesia, mean arterial blood pressure and heart rate were decreased in group I compared with group II. The amount of propofol required to maintain the target BIS was lower in group II compared with group I. The amount of intraoperative boluses of remifentanil required to

\* Corresponding author.

E-mail address: rihamhasaneen@yahoo.com (R. Hasanein).



maintain hemodynamics was lower in group II compared with group I. The amount of PCA morphine at 2 h in the PACU and the first post operative day were lower in group II compared with group I. Pain scores at 1 h and 2 h postoperatively were lower in group II compared to group I.  $P$  value  $<0.05$  was considered significant.

**Conclusion:** During laparoscopic gastric bypass in morbidly obese patients the co-administration of low dose ketamine and remifentanyl by continuous infusion provide more hemodynamic stability, satisfactory recovery profile and adequate postoperative pain relieve.

© 2011 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.

Open access under [CC BY-NC-ND license](#).

## 1. Introduction

The increasing incidence of obesity is a growing problem in national health care, which causes an increase in bariatric surgery [1]. Obese patients may be sensitive to respiratory depressant effect of opioid analgesic drugs and are more likely to require postoperative ventilation to avoid hypoxic episodes [2]. Remifentanyl hydrochloride, an ultra-short acting mu opioid receptor agonist, because of its ester structure, remifentanyl is submitted to wide spread ester hydrolysis, resulting in very rapid metabolism [3]. It is now currently used with propofol as total intravenous anesthesia (TIVA), it appears to produce moderate to mild hypotension [4]. Also an important concern with remifentanyl is the possibility of acute opioid tolerance or hyperalgesia that may increase postoperative pain [5]. Ketamine, a dissociative intravenous anesthetic. It was first used in human in 1965, it remains the subject of interest in clinical investigations [6]. The choice of general anesthesia for obese patients remains controversial [7].

The aim of this study was to evaluate the efficacy of continuous low dose ketamine infusion combined with remifentanyl and propofol infusion (TIVA) in patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGBP), on hemodynamic stability, postoperative analgesic requirement and recovery profile.

## 2. Patients and methods

After approval of the local Ethics Committee and patients informed written consent for elective laparoscopic Roux-en-Y gastric bypass (RYGBP) surgery, 60 morbidly obese patients (ASA physical status II or III), and age between 25 and 50 years, were enrolled in the study.

Patients with significant cardiac, respiratory, brain, liver or kidney diseases, or patients having allergy to the study drugs or patients unable to use post operative PCA were excluded from the study.

The patients were randomly allocated into two equal groups. Group I: received continuous infusion of (propofol 6–10 mg/kg/h guided by the BIS + remifentanyl 0.2 µg/kg/min + saline). Group II: received continuous infusion of (propofol 6–10 mg/kg/h guided by the BIS + remifentanyl 0.2 µg/kg/min + ketamine 1 µg/kg/min). All patients were planned to receive intravenous morphine patient controlled analgesia (PCA) postoperatively. PCA morphine prepared by adding 30 mg morphine sulphate to 27 ml normal saline, total volume 30 ml at concentration 1mg/ml, no bolus injection, PCA bolus 1 ml, no background infusion, lockout period 10 min, total amount of morphine in 4 h is 24 ml.

Patients and investigators recording data in the operating room were blinded to the treatment (ketamine or placebo), but anesthesiologist were aware of the treatment condition.

All drug doses were used according to true patient weight. In all patients antithrombotic treatment with low molecular weight heparin was started 12 h before the procedure. All patients received midazolam 3 mg with glycopyrrolate 0.2 mg intravenous bolus in the holding area.

In the operating room, standard monitors were applied: ECG, non invasive blood pressure, pulse oximetry, EtCO<sub>2</sub> (end tidal CO<sub>2</sub>), peripheral nerve stimulator, temperature probe, spirometry, urinary catheter and BIS (bispectral analysis of EEG, Aspect Medical, USA).

Before induction of anesthesia, patients received 10 mg metoclopramide, 50 mg ranitidine, and 8 mg dexamethazone i.v.

Anesthesia was induced after pre-oxygenation for 3 min by face mask with 100% oxygen, by remifentanyl (1 µg/kg), lidocaine (100 mg), propofol (1–2 mg/kg), and cisatracurium to facilitate endotracheal intubation (0.2 mg/kg).

The lungs were ventilated with a mixture of 50% air in oxygen in the pressure control mode with positive end-expiratory pressure (5–10 cm H<sub>2</sub>O) to maintain normocapnea (EtCO<sub>2</sub> 35–40 mm Hg).

For maintenance of anesthesia, continuous infusion of propofol 6–10 mg/kg/h was started; the rate of propofol was changed to maintain the BIS between 40 and 55.

In group I: remifentanyl infusion in dose of (0.2 µg/kg/min) was added.

In group II: combined infusion of remifentanyl (0.2 µg/kg/min) + ketamine (1 µg/kg/min) were added.

Cisatracurium given to all patients by boluses to maintain muscle relaxation (0.03 mg/kg) every 20–40 min based on neuromuscular stimulation.

All patients received a total volume of infusion of 3–4 L of Ringer's Lactate solution during anesthesia.

The infusions of both remifentanyl, saline in (group I) and remifentanyl, ketamine in (group II) were continued till removal of laparoscopy ports.

Patients were placed in the supine position. Laparoscopic RYGBP was performed through five abdominal trocars. Intra-abdominal pressure was maintained at 15 mm Hg.

At the end of surgery, anesthesia was maintained at a constant level during closure of the surgical incisions until the last stitch was completed.

Propofol was then turned off and the time to safe extubation was recorded. At the end of the operation muscle relaxant was reversed based on peripheral nerve stimulation. The extubation was performed when the patient gained 80% on Train-of-four stimulation. All patients were extubated and sent to

post anesthesia care unit (PACU), and standard post operative monitoring of the vital signs were applied: ECG, non invasive blood pressure, pulse oximetry, 2–3 L/min oxygen by nasal cannula were applied to all patients.

In the recovery room, time to response to verbal commands was recorded, subjective pain scores were obtained with a scale from 0 to 10, with 0 = no pain and 10 = worst pain, at 1 and 2 h post operatively by a nurse blinded to the study protocol.

Morphine patient controlled analgesia (PCA) was started once the patient pain score recorded 1–2 and continued in the ward for 24 h postoperative.

Patients were encouraged to ambulate in the first post operative day. Post operative pulmonary care included incentive spirometry and deep breathing exercises were encouraged.

### 3. Measurements

Mean blood pressure (mm Hg) and HR (beats/min) were measured before induction and every 5 min during surgery (recorded data T0: preoperative measures, T1 immediately after induction, T2: 5 min after induction, T3: 10 min after induction, T4: 15 min after induction, T5: 30 min after induction, T6: 60 min after induction, T7: 90 min after induction, T8: 2 h after induction, T9: 1st postoperative hour, T10: 2nd postoperative hour, T11: 6 h post operative, T12: 12 h post operative). Duration of anesthesia and surgery (min) were recorded. Bispectral index, total amount of propofol used (mg) and total amount remifentanyl used intraoperative were measured every hour. Total amount of morphine used in the 24 h postoperative period was calculated. The recovery profile after anesthesia including: time to spontaneous respiration, adequacy of respiration (Negative Inspiratory Force (NIF) > 50 CmH<sub>2</sub>O, tidal volume > 500 ml, saturation on O<sub>2</sub> > 98%) was recorded.

The incidence of postoperative nausea and vomiting (PONV), hallucinations were recorded and managed accordingly.

Early pain perception was measured by the time that passed between extubation and the first request of PCA (min). The outcome was the consumption of morphine by intravenous titration and by PCA during the first 4 h after surgery. Prolonged perception of pain was measured by patients' total consumption of morphine (mg) in 24 h.

### 4. Statistical analysis

Data were expressed as mean  $\pm$  standard deviation. Student's *t* test was used for each measurement within and between group comparisons. Pain score and the incidence of side effects were compared using Chi square test. *P* value of <0.05 was considered significant. All statistical analysis were done using Excel and SPSS package.

### 5. Results

Sixty patients were enrolled in the study with no exclusion. Patients demographic data are shown in Table 1. There were no differences in age, weight, height, body mass index, sex, ASA physical status or the duration of the operation between the two groups.

During anesthesia, mean arterial blood pressure (Fig. 1) and heart rate (Fig. 2) were significantly decreased in group I compared with group II, *P* < 0.05.

The total amount of propofol required to maintain the target BIS was significantly lower in group II compared with group I, *P* < 0.05.

The total amount of intra-operative boluses of remifentanyl required to maintain hemodynamic was significantly lower in group II compared with group I.

The total amount of PCA morphine at 2 h in the PACU and the first post operative day were significantly lower in group II compared with group I.

Pain scores at 1 h and 2 h postoperatively were significantly lower in group II compared to group I.


Blood pressure and heart rate at 1 h and 2 h postoperatively were clinically lower in group I compared to group II, but these differences were statistically not significant (Table 2).

Recovery profile, duration to spontaneous respiration, adequate respiration and safe extubation were shorter in group I compared to group II. These duration were statistically


**Table 1** Patient age, weight, height, body mass index, ASA physical status and duration of the procedure in minutes (mean  $\pm$  SD).

	Group I (n = 30)	Group II
Age (y)	27 $\pm$ 8	29 $\pm$ 6
Weight (kg)	119 $\pm$ 14	121 $\pm$ 19
Height (cm)	160 $\pm$ 5	162 $\pm$ 7
BMI (kg/m <sup>2</sup> )	40 $\pm$ 7	42 $\pm$ 4
Sex (M/F)	17/13	15/15
ASA (PS)	II (20), III (10)	II (18), III (12)
Duration of the procedure (min)	159 $\pm$ 27	156 $\pm$ 31

ASA (PS) = ASA physical status; BMI = body mass index.



**Figure 1** Mean arterial blood pressure changes (mm Hg) in both groups, intraoperative and postoperative. \**P* value <0.05 in group 2 compared to group 1. t0: preop data, t1: immediately after induction, t2: 5 min after, t3: 10 min after induction, t4: 15 min after induction, t5:30 min, t6: 60 min, t7: 90 min, t8: 2 h, t9: 1st postoperative hour, t10 2nd hour postoperative, t11: 6 h postoperative, t12: 12 h postoperative. T0, T1: not significant, T2–T7: significant, T8–T12: lower in Group1 but not significant.



**Figure 2** Mean heart rate changes (beats/min) in both groups, intra-operative and postoperative. \**P* value <0.05 in group 2 compared to group 1. t0: preop data, t1: immediately after induction, t2: 5 min after, t3: 10 min after induction, t4: 15 min after induction, t5: 30 min, t6: 60 min, t7: 90 min, t8: 2 h, t9: 1st postoperative hour, t10 2nd hour postoperative hour, t11: 6 h postoperative, t12: 12 h postoperative. T0, T1: not significant, T2–T7: significant, T8–T12: lower in Group1 but not significant.

**Table 2** Measurements made at the end of surgery (mean ± SD).

	Group I (n = 30)	Group II (n = 30)
PACU pain score (0–10) 1 h	6 (4–8)	3 (1–2)*
PACU pain score (0–10) 2 h	5 (2–5)	2 (1–3)*
PACU morphine (mg, 2 h)	10.4 ± 1.4	6.3 ± 10.6*
Total amount of morphine (mg), first 24 h postoperatively	47.4 ± 8	6.1* ± 40
PACU mean blood pressure (mm Hg/h)	90 ± 1	77 ± 9
PACU heart rate (min/h)	91 ± 4	83 ± 4
Total amount of intra-operative remifentanyl (µg)	350.5 ± 54.6	201.4 ± 54.3*
Total amount of intra-operative propofol (mg)	2200 ± 450	1503 ± 311*

\* *P* < 0.05 in group II compared to group I.

significant (*P* value <0.05) but clinically not significant. This duration started from end of surgery and discontinuation of propofol infusion (Table 3).

All patients after extubation were fully awake.

No differences in the incidence of postoperative nausea and vomiting or hallucination between both groups (Table 4).

## 6. Discussion

The problem of postoperative respiratory complications in obese patients is magnified by the use of narcotics during surgery and postoperative for pain control [8].

Opioids can cause pronounced respiratory complications in obese patients with obstructive sleep apnea.

Theoretically, co-administration of an opiate and ketamine decreases the doses needed for optimal analgesia below the

**Table 3** Recovery profile in minutes (mean ± SD).

	Group I (n = 30)	Group II (n = 30)
Response to verbal commands	3.4 ± 1.2	4.1 ± 0.7
Spontaneous respiration	4.6 ± 1	5.1 ± 0.5*
Adequate respiration	6.1 ± 1.5	6.3 ± 0.7
Safe extubation	7.5 ± 1.3	7.1 ± 0.7

\* *P* < 0.05 in group II compared to group I.

**Table 4** Incidence of side effects in both groups.

	Group I (n = 30)	Group II (n = 30)
No nausea and vomiting	27 (90%)	28 (93.4%)
Nausea	3 (10%)	2 (6.6%)
Vomiting	0 (0%)	0 (0%)
Hallucination	0 (0%)	0 (0%)

Data are presented as numbers (percentage).

required value of opioids when used alone and hence may decrease the incidence of side effects.

The results of our study showed that, ketamine (1 µg/kg/min) when added to propofol-remifentanyl during laparoscopic RYGBP, counteracted the hemodynamic changes induced by remifentanyl, decreased propofol consumption, decreased pain score in the postoperative period, decreased morphine PCA consumption and also resulted in a better recovery profile than using remifentanyl-propofol alone.

Ketamine-related side effects such as hallucinations, unpleasant dreams, and delirium did not occur in our patients, as we used low dose continuous infusion, such side effects have been related to large doses used for general anesthesia.

In the group received remifentanyl alone patients developed hypotension and bradycardia most probably due to remifentanyl.

Previous studies have shown an unacceptable incidence of bradycardia associated with the use of remifentanyl in the absence of a vagolytic agent [9]. However, opioid-induced bradycardia is gradually accepted to be vagally mediated [10].

It could be due to the impairment of baroreflex regulatory mechanisms caused by propofol infusion [11].

Hypertension and bradycardia have been found with the use of remifentanyl when combined with intravenous agent [12] or general anesthetics [13].

In contrast, to these results Glass et al. found increased arterial blood pressure and heart rate after injecting remifentanyl intravenously alone without any other agents, in healthy un-premeditated volunteers [14].

Degaute et al. found that remifentanyl hydrochloride causes consistent and maintained hypotension [15].

Sammons, AW et al. found profound hypotension caused by remifentanyl when compared to fentanyl used for day case microlaryngoscopy [16].

In our study, in the ketamine-remifentanyl group the heart rate and mean arterial blood pressure did not decrease below the preoperative values, most probably due to the catecholamine release of ketamine, which is commonly resulting in both tachycardia and hypertension [17], an action that can attenuate remifentanyl effects.



In agreement of our study, Katz et al. found that using alfentanil with ketamine resulted in obtunding the tachycardia and hypertension caused by ketamine after intubation and little or no change in HR or ABP [18].

In the postoperative period, the hemodynamic measurements were maintained within normal values in the ketamine-remifentanyl group, while in the patients received remifentanyl alone there was slight increase in mean blood pressure, which could be explained by the counteracting effect of ketamine on remifentanyl induced hyperalgesia.

Regarding recovery from anesthesia, the remifentanyl group patient recovered quicker than ketamine-remifentanyl group, although it was statistically significant; clinically it was not significant. This is due to the short half-life of remifentanyl which is 8–10 min [14]. The presence of an ester side chain allow rapid breaking down of remifentanyl by non-specific esterases to nearly inactive metabolites, causing rapid recovery from intra-operative infusion [19].

The time to the first PCA dose required in the PACU, was shorter in the remifentanyl group than in the ketamine-remifentanyl group, this could be due to the hyperalgesia and the development of opioid-induced tolerance related to remifentanyl infusion. This is due to the activation of N-methyl-D-aspartate (NMDA) receptors in the CNS, and subsequent biochemical process leading to central sensitization, increase spinal dynorphin activity and activation of intracellular protein kinase C<sup>29</sup> [20].

Ketamine, a NMDA receptor antagonist used in the ketamine-remifentanyl group may substantially enhance opiate-induced anti-nociception [20].

Frederic Adam and his colleagues [21], evaluated the effect of 1.5 µg/kg/min ketamine for postoperative pain relieve and total consumption of morphine after total knee arthroplasty. They found that ketamine group required less morphine than the control group which helped in early knee mobilization.

Subra Maniam [22], concluded that the addition of ketamine either intravenous bolus or continuous infusion is more effective than morphine alone, while intravenous PCA of ketamine and morphine was not more effective than intravenous PCA morphine alone.

The result of the present study showed that continuous intra-operative infusion of low dose ketamine combined with remifentanyl resulted in less postoperative pain score and less morphine consumption than using remifentanyl infusion alone. Ketamine may produce its anti-nociception by activation of the descending pain inhibitory mono-aminergic pathways [23], which is expressed by alpha-2-adrenoceptor at the spinal level [24]. Although anti-nociception of ketamine intra-thecal in rats is reversed by naloxone [23], analgesia in humans by systemic ketamine up to 300 µg/kg, cannot be reversed [25], which means that mono-aminergic activation, more than the mu receptor agonist activity, may be present in the anti-nociception effect produced by the analgesic dose of ketamine.

The affinity of ketamine for NMDA receptors is more than an order of magnitude higher than that for mu receptors [25] and several-fold higher than that for monoamine transporter sites or other non-NMDA receptors (i.e. Acetylcholinesterase and the epsilon receptors) [26], suggesting that the smaller the dose, the more selective is the ketamine interaction with NMDA receptors.

In consistent of our study Stubhug et al., showed that in human continuous infusion of small-dose ketamine for 48 h,

increases the time for first use PCA-morphine and reduced cumulative morphine [27].

Other studies have found that a marked decrease in consumption of opiate and/or pain intensity by systemic [28] or epidural [29] co-administration of ketamine and opiates.

In conclusion, our results demonstrated that during laparoscopic RYGBP in morbidly obese patients the co-administration of low dose ketamine and remifentanyl by continuous infusion provide more hemodynamic stability, satisfactory recovery profile and adequate postoperative pain relieve.

## References

- [1] Hoff RE, Sprung J, Sarr MG, Wedel DJ Anesthesia for a patient with more obesity using dexmedetomidine without narcotics. *Can J Anesth* 2005;52:176–80.
- [2] Fernandez Jr AZ, Demaria EJ, Tichansky DS, Kellum JM, Wolfe LG, Meador J, et al. Multivariate analysis risk factors for death following gastric by pass for treatment of morbid obesity. *AnnSurg* 2009;239:698–702.
- [3] Graybar GB, Bready LL. Anesthesia for renal transplantation Boston, Martinus Nijhoff; 1987.
- [4] Schüttler J, Albrecht S, Breivik H, et al. A comparison of remifentanyl and Alfentanil in patients undergoing major abdominal surgery. *Anesthesia* 1997;52:307.
- [5] Angis MS, Koppert W, Pahl HLI, et al. Sort term infusion of mu-opioid agonist remifentanyl in human causes hyperalgesia during withdrawal. *Pain* 2003;106:49.
- [6] Friesen RH, Morrison JE. The role of ketamine in the current practice of pediatric anesthesia 2003;4:97.
- [7] Salihoglu, Karaca S, Kose Y, Zengin K, Taskin M Total intravenous anesthesia versus single breath technique and anesthetic maintenance with sevoflurane for bariatric operations. *Obesity Surg* 2001;11:496–501.
- [8] Javahert S, Abraham WT, Brown C, Nishiy ama H, Giesting R, Wagoner LE Prevalence of obstructive sleep apnea and periodic limb movement in 45 subjects with heart transplantation. *Euro Heart J* 2004;25:260–6.
- [9] Escalamado RM, Glen MG, Mcculloch TM, Cummings CW Peri-operative complications and risk factors in the surgical treatment of obstructive sleep apnea syndrome. *Laryngoscope* 1989;99:1125–9.
- [10] Reitan JA, Strenger KB, Wymore MC, Martucci RW Central vagal control of fentanyl-induced bradycardia during halothane anesthesia. *Anesth Analg* 1978;57:31.
- [11] Ebert TJ, Muzi M, Berens R, Goff D, Kampine JP Sympathetic responses to induction of anesthesia in humans with propofol or etomidate. *Anesthesiology* 1992;76:725.
- [12] Hogue Jr CW, Bowdle TA, O'leary C, et al. A multicentre evaluation of total intravenous anesthesia with remifentanyl and propofol for elective inpatient surgery. *Anesth Analg* 1996;83:279.
- [13] Schüttler J, Albrecht S, Breivik H, et al. A comparison of remifentanyl and alfentanil in patients undergoing major abdominal surgery. *Anesthesia* 1997;52:307.
- [14] Glass PSA, Hardman D, Kamiyama Y, et al. Preliminary pharmacokinetics and pharmacodynamics of an ultra short-acting opioid: remifentanyl (GI87084 B). *Anesth Analg* 1993;77:1031.
- [15] Degoute CS, Christian S, et al. Remifentanyl and controlled hypotension; comparison with nitroprusside or esmolol during tympanoplasty. *Can J Anaesth* 2001;20–7.
- [16] Sammons AW, Serafini I Remifentanyl versus fentanyl in day-case microlaryngoscopy; hemodynamic and recovery times. *Brit J Anaesth* 2001;87:943.

- [17] White PF Comparative evaluation of intravenous agents for rapid sequence induction-thiopental, ketamine and midazolam. *Anesthesiology* 1982;57:279.
- [18] Katz RI, Levy A, Slepian B, Sobel B, Lagasse RS Haemodynamic stability and ketamine-alfentanil anaesthetic induction. *Brit J Anaesth* 1998;81:702.
- [19] Thompson JP, Robotham DJ Remifentanil – an opioid for the 21st century. *Brit J Anaesth* 1996;76:341.
- [20] Mao J, Price DD, Mayer DJ Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. *Pain* 1995;62:269.
- [21] Frederic ADAM et al. Small-dose ketamine infusion improves postoperative analgesia and rehabilitation after total knee arthroplasty. *Anesth Analg* 2005;100:745.
- [22] Subra Maniam K, Subramaniam MB, Stienbrook R Ketamine added to opioid analgesia: a quantitative and qualitative systemic review of controlled clinical trials. *Anesth Analg* 2004;482–95.
- [23] Pekoe GM, Smith DJ The involvement of opiates and monoaminergic neuronal systems in the analgesic effects of ketamine. *Pain* 1982;12:57.
- [24] Howe JR, Wangj Y, Yaksh TL Selective antagonism of the antinociceptive effect of intrathecally applied alpha adrenergic agonists by intrathecal prazosin and intrathecal yohimbine. *J Pharmacol Exp Ther* 1983;224:552.
- [25] Maurset A, Scuglundl A, Hustveit O, Øye L Comparison of ketamine and pethedine in the experimental and postoperative pain. *Pain* 1989;36:37.
- [26] Smth DJ, Azzaro AJ, Saldivar SB, et al. Property of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. *Neuropharmacology* 1981;20:391.
- [27] Stubhaug A, Breivik H, Eide PK, et al. Mapping of punctuate hyperalgesia around surgical incision demonstrate that ketamine is a powerful suppressor to central sensitization to pain following surgery. *Acta Anaesthiol Scand* 1997;41:1124.
- [28] Javery KB, Ussery TW, Steger HG, Cocclouch GW Comparison of morphine and morphine with ketamine for postoperative analgesia. *Can J Anaesth* 1996;43:212.
- [29] Chia YY, Liu YC, et al. Adding ketamine in a multimodal patient-controlled epidural regimen reduces postoperative pain and analgesic concentration. *Anaesth Analg* 1998;86:1245.